Antibody Drug Conjugates (ADCs)
We studied the high failure rates of ADCs going into the clinic. Aarvik was built around the answers to these fundamental questions.
ADCs face limitations
- Indications restricted by target copy number
- Efficacy constrained by maximum tolerated dose (MTD) and off-target toxicity
- Developability risks faced by new multivalent antibody platforms
Many ADCs have failed
Status of 482 ADCs that have progressed into the clinic as of August 2025*
*Beacon Targeted Therapies Clinical Trials and Pipeline Database
MTD limits efficacy, primarily due to off-target toxicity caused by macropinocytosis
Lower minimum effective dose (MED) and maintain or improve MTD compared to the current generation of ADCs
*Tap image to enlarge
Gen 1 ADCs
- Highly expressed receptors
- Very potent payloads
- Gen 1 conjugation
Gen 2 ADCs
- Highly expressed receptors
- Less potent payloads
- Gen 2 conjugation
Aarvik MUTTA™ ADCs
- Combine two or more low copy
number receptors - Leverage valency and architecture
- Utilize improved conjugation,
linkers and payload matching
*Tap image to enlarge
*Tap image to enlarge
Target
Antibody
Payload
Linker
Conjugation
Expression-based
screening for
target pairs
Combined copy
number across
targets
Improved
internalization
Multitarget /
Multivalent (up
to 4)
Readily
manufacturable
Multiple formats
Lorem ipsum dscnc
Modular
With or without
common light
chain
Function
blocking (where
feasible)
Binder
architecture
Novel or existing
CDRs
Proprietary
payloads
Diversified
payloads
Payload
matching
Proprietary
hydrophilic
cleavable linkers
Site-specific
conjugation
Monospecific ADCs
Demonstrate limited target dependent potency, especially on heterogeneously expressed solid tumors
Bispecific MUTTA™ ADCs
- Apply OR-gate approach to kill single or dual antigen-expressing tumor cells
- Overcome antigen escape limitation seen with monospecific ADCs
*Tap image to enlarge
*Tap image to enlarge
Target
Antibody
Payload
Linker
Conjugation
Expression-based
screening for
target pairs
Combined copy
number across
targets
Improved
internalization
Multitarget /
Multivalent (up
to 4)
Readily
manufacturable
Multiple formats
Lorem ipsum dscnc
Modular
With or without
common light
chain
Function
blocking (where
feasible)
Binder
architecture
Novel or existing
CDRs
Proprietary
payloads
Diversified
payloads
Payload
matching
Proprietary
hydrophilic
cleavable linkers
Site-specific
conjugation
Monospecific ADCs
Demonstrate limited target dependent potency, especially on heterogeneously expressed solid tumors
Bispecific MUTTA™ ADCs
- Apply OR-gate approach to kill single or dual antigen-expressing tumor cells
- Overcome antigen escape limitation seen with monospecific ADCs